2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitors
2006
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB.
Rich M, Socci A, Mitnick C, Nardell E, Becerra M, Bonilla C, Bayona J, Seung K, Furin J, Farmer P, Mukherjee J. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. The International Journal Of Tuberculosis And Lung Disease 2006, 10: 290-6. PMID: 16562709.Peer-Reviewed Original ResearchConceptsPrevious treatment exposureRetreatment regimensDrug susceptibility testingPatient populationDST patternsTreatment exposureGroup 1Likely effective drugsMDR-TB regimensSecond-line drugsDrug susceptibility patternsNational Tuberculosis ProgrammeDifferent patient populationsAnti-tuberculosis agentsIndividualized regimensMDR-TBTuberculosis ProgrammeEffective anti-tuberculosis agentsSusceptibility patternsDST resultsRegimensEffective drugsPatientsGroup 4Susceptibility testing
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply